SCF ENCYCLOPEDIA ENTRY
NEONATAL HERPES SIMPLEX VIRUS (NEONATAL HSV)
SCF-RDOS Maternal–Neonatal Viral Transmission, Neurocutaneous Infection & Developmental Viral Injury Registry
Disease Classification
Congenital & Perinatal Infection / Neonatal Viral Disease / Neuroinfectious Disorder / Maternal–Fetal Transmission Syndrome / Developmental Infectious Disease
Master Registry Code
SCF-NHSV-0001
I. DEFINITION
Neonatal Herpes Simplex Virus (Neonatal HSV) is a severe perinatal viral infection acquired before birth, during delivery, or shortly after birth through transmission of herpes simplex virus (HSV) from an infected mother or caregiver to the newborn.
The causative viruses are:
- HSV-1
- HSV-2
Neonatal HSV is among the most serious neonatal viral infections because of its ability to rapidly disseminate and invade:
- Skin
- Eyes
- Oral mucosa
- Central nervous system
- Liver
- Lungs
- Adrenal glands
Without treatment, mortality can be extremely high, particularly in disseminated disease.
Within the Synergistic Compatibility Framework (SCF), Neonatal HSV is modeled as a:
- Maternal–neonatal viral transmission disorder
- Neurocutaneous dissemination syndrome
- Developmental antiviral defense failure architecture
- Viral neuroinflammatory injury cascade
II. CORE SCF ETIOPATHOGENIC PRINCIPLE
Central SCF Thesis
Neonatal HSV develops when herpes simplex virus breaches maternal–fetal or maternal–neonatal protective barriers and infects an immunologically immature infant, allowing rapid viral replication, neural invasion, systemic dissemination, and inflammatory tissue injury.
This propagates through:
- Maternal infection
- Viral shedding
- Neonatal exposure
- Viral entry
- Local replication
- Neural/systemic spread
- Organ injury
III. MAJOR NEONATAL HSV REGISTRY
A. SKIN–EYE–MOUTH (SEM) DISEASE
Most Localized Form
Affected structures:
- Skin
- Eyes
- Oral mucosa
Typical manifestations:
- Vesicles
- Oral lesions
- Conjunctivitis
Best prognosis when treated early.
B. CNS HSV DISEASE
Neuroinvasive Form
Involves:
- Brain
- Meninges
- Temporal lobes
- Neural pathways
Manifestations:
- Encephalitis
- Seizures
- Altered consciousness
Associated with:
- Neonatal Seizures
C. DISSEMINATED HSV
Most Severe Form
Systemic viral dissemination affecting:
- Liver
- Lungs
- Brain
- Bloodstream
- Adrenal glands
May mimic:
- Neonatal Sepsis
D. CONGENITAL HSV
Rare form acquired in utero.
Associated with:
- Growth restriction
- Microcephaly
- Eye abnormalities
- Skin scarring
IV. ETIOLOGIC DOMAINS
A. PRIMARY MATERNAL HSV INFECTION
Highest-risk scenario.
Occurs when maternal infection develops:
- During late pregnancy
- Near delivery
Transmission risk is greatest because protective maternal antibodies have not yet formed.
B. RECURRENT MATERNAL HSV
Lower transmission risk due to:
- Maternal antibody protection
Still capable of transmission.
C. INTRAPARTUM EXPOSURE
Most common route.
Occurs through:
- Vaginal delivery
- Exposure to infected genital secretions
D. POSTNATAL TRANSMISSION
May occur through:
- Oral herpes lesions
- Direct caregiver contact
E. IMMUNOLOGIC IMMaturity
Neonates possess:
- Limited T-cell function
- Reduced antiviral immunity
- Immature innate defenses
V. SCF MULTI-OMIC PATHOGENESIS
A. VIRAL ENTRY LAYER
HSV enters through:
- Skin
- Mucosa
- Conjunctiva
B. REPLICATION LAYER
Virus replicates within:
- Epithelial cells
Resulting in:
- Vesicle formation
- Cellular destruction
C. NEURAL INVASION LAYER
HSV spreads through:
- Peripheral nerves
- Sensory ganglia
Resulting in:
- CNS involvement
D. SYSTEMIC DISSEMINATION LAYER
Produces:
- Viremia
- Multiorgan infection
E. INFLAMMATORY RESPONSE LAYER
Includes:
- Cytokine activation
- Neuroinflammation
- Endothelial dysfunction
F. DEVELOPMENTAL INJURY LAYER
Results may include:
- Cognitive impairment
- Motor dysfunction
- Epilepsy
- Developmental delay
Associated with:
- Developmental Delay
VI. SCF FAULT-TIER ARCHITECTURE
SCF Tier | Neonatal HSV Fault |
Tier I | Maternal viral shedding |
Tier II | Neonatal exposure |
Tier III | Viral replication |
Tier IV | CNS/systemic dissemination |
Tier V | Organ injury and developmental impairment |
SCF fault progression models neonatal HSV as escalation from viral exposure into widespread neonatal infectious injury.
VII. MAJOR CLINICAL MANIFESTATIONS
A. CUTANEOUS FINDINGS
Includes
- Vesicular lesions
- Blistering rash
- Skin ulceration
B. OCULAR FINDINGS
Includes
- Conjunctivitis
- Keratitis
- Retinal injury
C. SYSTEMIC FINDINGS
Includes
- Fever
- Hypothermia
- Poor feeding
- Lethargy
- Irritability
D. NEUROLOGIC FINDINGS
Includes
- Seizures
- Apnea
- Encephalopathy
- Altered consciousness
Associated with:
- Neonatal Encephalopathy
VIII. MAJOR COMPLICATIONS
Neurologic
- HSV encephalitis
- Epilepsy
- Intellectual disability
- Cerebral injury
Hepatic
- Fulminant hepatitis
- Liver failure
Pulmonary
- Viral pneumonitis
- Respiratory failure
Hematologic
- Coagulopathy
- Disseminated intravascular coagulation
Associated with:
- Disseminated Intravascular Coagulation
Mortality
Highest in:
- Disseminated HSV
- Untreated CNS disease
IX. SCF RHENOVA INTERPRETATION
Within the SCF–RHENOVA framework, Neonatal HSV represents:
- Viral bioenergetic variance
- Neuroimmune coordination failure
- Maternal–neonatal barrier breach
Key RHENOVA Signatures
- Viral replication overload
- Neuroinflammation
- Mitochondrial stress
- Endothelial injury
- Immune dysregulation
X. SCF DBI INTERPRETATION
Under the SCF Decentralized Biological Intelligence (DBI) framework, Neonatal HSV disrupts:
- Antiviral defense networks
- Neurodevelopmental communication systems
- Maternal–neonatal immune coordination pathways
- Cellular danger-response architecture
- Organ-level adaptation algorithms
This transforms localized infection into distributed developmental infectious injury.
XI. SCF PATHOGENESIS LOGIC MODEL
Reconnaissance Phase
HSV identifies vulnerable:
- Mucosal surfaces
- Neonatal immune gaps
Exploitation Phase
Virus establishes:
- Local infection
- Cellular replication
Privilege Escalation Phase
Virus gains access to:
- Neural pathways
- Bloodstream
Persistence Phase
Produces:
- Latent infection
- Reactivation potential
System Failure Phase
Results in:
- CNS disease
- Organ failure
- Developmental injury
XII. DIAGNOSTIC ARCHITECTURE
Clinical Assessment
Evaluate for:
- Vesicular lesions
- Sepsis-like illness
- Neurologic abnormalities
- Maternal HSV history
Laboratory Testing
Gold Standard
HSV PCR from:
- Blood
- CSF
- Skin lesions
- Mucosal surfaces
Neurodiagnostic Evaluation
Includes:
- Brain MRI
- EEG
- Lumbar puncture
Organ Assessment
Includes:
- Liver enzymes
- Coagulation studies
- CBC
- Respiratory evaluation
XIII. SCF PCR MODEL (PREVENTATIVE–CURATIVE–RESTORATIVE)
A. PREVENTATIVE
Maternal Prevention
Includes:
- HSV screening awareness
- Antiviral suppression in late pregnancy
Common agent:
- Valacyclovir
Delivery Prevention
Cesarean delivery recommended when:
- Active genital HSV lesions are present
B. CURATIVE
First-Line Therapy
Acyclovir
Administered intravenously.
Supportive Care
Includes:
- NICU monitoring
- Respiratory support
- Seizure management
- Fluid management
Severe Disease Management
Includes:
- Intensive care
- Organ support
- Extended antiviral treatment
C. RESTORATIVE
Long-Term Follow-Up
Includes:
- Neurodevelopmental assessment
- Hearing evaluation
- Vision monitoring
- Rehabilitation services
XIV. ORIGIN-OF-DISEASE & CYTOGENESIS PROGRESSION TIMELINE
Stage | Cytogenic Event | Clinical Consequence |
Stage 1 | Maternal HSV infection | Viral shedding |
Stage 2 | Neonatal exposure | Viral entry |
Stage 3 | Local epithelial replication | SEM disease |
Stage 4 | Neural or hematogenous spread | CNS/systemic disease |
Stage 5 | Organ injury | Clinical manifestations |
Stage 6 | Recovery or sequelae | Long-term outcomes |
Cytogenesis Loci
Primary loci:
- Skin
- Oral mucosa
- Eyes
- Sensory ganglia
- Central nervous system
Secondary loci:
- Liver
- Lungs
- Adrenal glands
- Endothelium
- Immune tissues
XV. SCF API DISCOVERY & THERAPEUTIC PRIORITIES
High-Priority Therapeutic Domains
Antiviral Targets
- HSV DNA polymerase
- Viral entry proteins
- Viral fusion machinery
Neuroprotective Targets
- Neuroinflammation
- Oxidative stress
- Mitochondrial dysfunction
Maternal–Fetal Protection Targets
- Viral transmission blockade
- Placental barrier enhancement
- Passive immune protection
XVI. SCF SUMMARY
Neonatal HSV = Maternal–Neonatal Viral Transmission and Neuroimmune Synchronization Failure Syndrome
Within SCF:
- Neonatal HSV is a life-threatening viral infection caused by HSV-1 or HSV-2 transmission to a newborn.
- Disease may present as localized SEM disease, CNS encephalitis, or disseminated multiorgan infection.
- Primary maternal infection near delivery carries the greatest transmission risk.
- Rapid diagnosis and intravenous acyclovir therapy dramatically improve survival.
- Long-term outcomes depend on the degree of CNS involvement and timeliness of treatment.
- Future SCF therapeutic priorities focus on transmission prevention, neuroprotection, antiviral optimization, and preservation of developmental integrity.
MASTER REGISTRY INDEX
SCF-NHSV-0001 — Neonatal HSV
SCF-NHSV-ENTRY-0002 — Viral Entry Layer
SCF-NHSV-REPL-0003 — Viral Replication Layer
SCF-NHSV-CNS-0004 — Neuroinvasion Layer
SCF-NHSV-DISS-0005 — Disseminated Disease Layer
SCF-NHSV-RHENOVA-0006 — Viral Bioenergetic Variance Layer
SCF-NHSV-DBI-0007 — Neuroimmune Informational Dysregulation Layer
SCF-NHSV-PCR-0008 — Preventative–Curative–Restorative Management Framework